Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 29, 2024
Daily News
July 29, 2024
- MHLW Mulls System to Seek Expert Input for Patent Linkage
July 29, 2024
- LDP Members Fret over Easier Access to Abortion Pill Mefeego
July 29, 2024
- Off-Year Revision Debate to Follow Honebuto Policy: MHLW Bureau Chief
July 29, 2024
- AZ, United Immunity to Tie Up on Drug Delivery Tech Research
July 29, 2024
- Otsuka Ups H1 Earnings Forecast on Brisk Business
July 29, 2024
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- EU Regulator Rejects Leqembi, Eisai to Seek Re-Examination
July 29, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…